Health Canada open data (page 17)
Health Canada publishes 2,987 open datasets on CanQuery: 58 with live tables. Preview tables, export CSV and follow original downloads.
- Datasets
- 2987
- Queryable datasets
- 58
- Mappable datasets
- 0
Datasets
- Notice - Revision to the Post-Notice of Compliance (NOC) Changes - Notices of Change: Level III Form
- Notice - Publication of the Health Canada Guidance Document: Use of Certificates of Suitability as supporting information in Drug Submissions
- Notice - Release of the Final Guidance Document: Drug Submissions Relying on Third-Party Data (Literature and Market Experience)
- Notice - Release of the Final Guidance Document: Notice of Compliance with Conditions (NOC/c)
- Notice - Updated Screening Criteria for Generic Drug Submissions
- Notice: Revision to the Guidance Document Management of Drug Submissions and Applications (August 2022)
- Notice: Updates to the Guidance Document: Fees for the Review of Drug Submissions and Applications
- Policy Issues: Filing of Supplemental New Drug Submissions, Supplemental Abbreviated New Drug Submissions, Notifiable Changes and Cross-referenced Submissions
- Preparation of the Quality Information for Drug Submissions in the CTD Format: Biotechnological/ Biological (Biotech) Products: Guidance for Industry
- Preparation of veterinary Drug Identification Number submissions
- Priority Review of Drug Submissions (Therapeutic Products)
- Priority Review of Drug Submissions Policy
- Public Release of Clinical Information in Drug Submissions and Medical Device Applications
- Publication of the Health Canada Guidance Document: Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs)
- Quality Overall Summary - Chemical Entities (Applications for Drug Identification Number Submissions) (QOS-CE (DINA))
- Service Standards for Drug Submission Evaluations (Pharmaceuticals and Biologic Products) under the Food and Drug Regulations - Health Canada
- Service Standards for Veterinary Drug Submission Evaluations under the Food and Drug Regulations
- Drug Identification Number (DIN)
- Drug identification numbers (DINs) - guidance documents
- Drug product announcements
- Drug products legislation and guidelines
- Fact Sheets – Drug products
- Fact Sheets – Medical devices
- Fees for human drugs
- Guidance Document Post-Drug Identification Number (DIN) Changes
- Summary - Cancellation of a Drug Identification Number (DIN) and Notification of the Discontinuation of Sales
- Summary: Guidance Document - Drug Identification Numbers for Schedule C Drugs (Radiopharmaceuticals and Kits)
- Applying for a Drug Identification Number (DIN) for a disinfectant drug during the COVID-19 pandemic: COVID-19-related application flexibilities
- Applying for a Drug Identification Number (DIN) for a disinfectant drug during the COVID-19 pandemic: Determine your application stream
- Applying for a Drug Identification Number (DIN) for a disinfectant drug during the COVID-19 pandemic: Purpose and eligible products
- Applying for a Drug Identification Number (DIN) to distribute or sell hand sanitizer: Eligible products
- Applying for a Drug Identification Number (DIN) to distribute or sell hand sanitizer: Purpose and scope
- Assignment of Drug Identification Numbers for Drug Products in Kits
- Draft Guidance for Industry: Quality Guidance: Applications for Drug Identification Numbers (DINAs) for Pharmaceuticals
- Guidance on evaluation fees for human drugs and disinfectants: Credit for missed performance standard
- A guide to the new disaggregated data questionnaire for drug submissions
- Draft Guidance Document: Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs)
- Draft Guidance Document: Use of Certificates of Suitability as supporting information in Drug Submissions
- Draft guidance on management of rolling reviews for drug submissions: Overview
- Draft guidance on management of rolling reviews for drug submissions: Rolling review process, eligibility
- Draft guidance on management of rolling reviews for drug submissions: Applying for rolling review status
- Guidance on evaluation fees for human drugs and disinfectants: Invoicing, fee payment and mitigation measures
- Draft guidance on management of rolling reviews for drug submissions: Filing a submission
- Draft guidance on management of rolling reviews for drug submissions: Performance targets and standards, cancellation
- Draft guidance on management of rolling reviews for drug submissions: Fees
- Drug and Health Product Submissions Under Review (SUR): New drug submissions completed
- Drug and Health Product Submissions Under Review (SUR): New drug submissions under review
- Drug and Health Product Submissions Under Review (SUR): Supplemental submissions completed
- Guidance Document: Drug Submissions Relying on Third-Party Data (Literature and Market Experience)
- Guidance Document: Fees for the Review of Veterinary Drug Submissions and Applications